WASHINGTON – EWG Action Fund supports Sens. Edward J. Markey (D-Mass.) and Barbara Boxer (D-Calif.) in their effort to find out how states and schools across the U.S. have implemented a 1986 law designed to protect students, teachers and other school employees from the dangers of asbestos. In letters sent yesterday[…]
From the blog
Proposal Aims to Help Americans Spot Asbestos Products
March 10, 2015 Washington, D.C. – Legislation introduced today by Sen. Richard Durbin (D-Ill) would set up a federal online database of information about products that contain asbestos and where those items are likely to be found. The Reducing Exposure to Asbestos Database (READ) Act (S. 700) would require all those who[…]
Lethal and Still Legal: Asbestos Flows into U.S. Ports
New National Campaign to Raise Awareness of Continuing Threats from Asbestos March 10, 2015 Washington, D.C. – Many Americans believe asbestos was banned decades ago. But the deadly substance remains legal, with more than 8 million pounds entering U.S. ports since 2006, according to an analysis of federal trade data released today by[…]
New Congress Aligns with Asbestos Industry
Pushes for Bill on World Cancer Day that Denies Justice for Victims Contact: Monica Amarelo (202) 667-6982 press@ewgactionfund.com For Immediate Release: Wednesday, February 4, 2015 WASHINGTON – World Cancer Day should serve as a reminder that asbestos can cause cancer and kill. Instead, the new Congress today underscored how tone deaf[…]
FACT Act Favors Asbestos Industry Over Justice, Public Health
Would waste assets meant to help victims, invade privacy and delay compensation Contact: Monica Amarelo (202) 667-6982 press@ewgactionfund.com For Immediate Release: Wednesday, January 28, 2015 WASHINGTON — Legislation re-introduced by Rep. Blake Farenthold, R-Texas, would place new burdens on asbestos bankruptcy trusts, slowing compensation to victims suffering from fatal asbestos-related diseases[…]
Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Purpose: This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient refusal or withdrawal of patient consent, or unacceptable toxicity.
MSB0010718C in Solid Tumors
Purpose: This is a Phase 1, open-label, dose-escalation trial of MSB0010718C [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment has been closed for the following cohorts: non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and metastatic colorectal cancer (mCRC).
Lung cancer is more than a smokers’ disease
The world seems to turn pink each October in honor of Breast Cancer Awareness Month, but little recognition is given to the month that follows. November marks Lung Cancer Awareness Month, intended to educate the public about the leading cause of cancer deaths among men and women in the United[…]
Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population (ABOCA1)
Purpose: This is a single-arm phase II trial to assess the biological activity (in a sub-cohort using a Simon two-stage Phase II design) and toxicity of Artichoke Whole Phytocomplex Concentrate (WPC). The objective of the study is to explore the potential for a non-toxic phytocomplex extract from the artichoke plant as a chemoprevention agent.
SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
Purpose: SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.
Skip to content